Tesamorelin 5mg

Tesamorelin 5mg is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed for research and laboratory use. Tesamorelin is a stabilised 44-amino acid GHRH peptide with a trans-3-hexenoic acid modification at the N-terminus, conferring enhanced stability relative to endogenous GHRH(1–44). It has been investigated in preclinical and clinical research settings for its effects on GH and IGF-1 axis stimulation, visceral adiposity, and metabolic regulation. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHRH receptor pharmacology, GH axis modulation, and metabolic biology. Store in a cool, dry place away from direct light. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: Tesamorelin (synthetic GHRH analogue) Concentration: 5mg per vial Molecular Formula: C₂₂₁H₃₆₆N₆₀O₆₇S Molecular Weight: 5,202.8 g/mol Structure: 44-amino acid GHRH analogue with N-terminal trans-3-hexenoic acid modification CAS Number: 86168-78-7 Purity: ≥98% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder pH (reconstituted): 4.0–5.5 Endotoxin Level: <5 EU/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Sterile water for injection Intended Use: Laboratory and research applications only

Storage Before Reconstitution: Store in original sealed vial at 2–8°C, protected from direct light and moisture. Stable for 24 months from manufacture date. Do not freeze. Minimise temperature fluctuations. Storage After Reconstitution: Store reconstituted solution at 2–8°C, protected from light. Use aseptic technique throughout. Avoid repeated freeze-thaw cycles; if freezing is necessary, use single-use aliquots at −20°C for up to 3 months. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Tesamorelin: Design and GHRH Receptor Pharmacology
   Falutz J, et al. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
   Pivotal Phase 3 clinical research study demonstrating tesamorelin’s ability to significantly reduce visceral adipose tissue and elevate IGF-1 levels via sustained GHRH receptor activation, establishing its pharmacodynamic profile and providing the key translational reference for tesamorelin GH-axis research.
2. Tesamorelin and GH/IGF-1 Axis Stimulation
   Falutz J, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
   Randomised, placebo-controlled trial with safety extension evaluating tesamorelin’s sustained effects on GH and IGF-1 secretion and visceral fat reduction, providing long-term pharmacodynamic and tolerability data relevant to GHRH analogue research protocols.
3. GHRH Receptor Structure and Agonist Binding
   Mayo KE, et al. (1992). Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 6(10), 1734–1744. https://doi.org/10.1210/mend.6.10.1333056
   Reports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which tesamorelin exerts its GH-releasing effects and providing the structural and signalling context for GHRH receptor agonist research.
4. Tesamorelin and Visceral Adiposity: Metabolic Research Context
   Stanley TL, et al. (2012). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
   Randomised clinical trial demonstrating tesamorelin’s significant reduction of visceral and hepatic fat via GH/IGF-1 axis activation, providing quantitative metabolic and body composition data relevant to researchers studying GHRH analogue effects on lipid metabolism and adipose tissue biology.
5. Tesamorelin and Cognitive Function Research
   Baker LD, et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 69(11), 1420–1429. https://doi.org/10.1001/archneurol.2012.1970
   Randomised controlled trial investigating tesamorelin’s effects on cognitive function in older adults and those with mild cognitive impairment, demonstrating improvements in executive function and verbal memory — expanding the research scope of GHRH analogue studies into neuroendocrine and cognitive biology.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.